Cisse, Ouma
Quraishi, Muzthahid
Gulluni, Federico
Guffanti, Federica
Mavrommati, Ioanna
Suthanthirakumaran, Methushaa
Oh, Lara C. R.
Schlatter, Jessica N.
Sarvananthan, Ambisha
Broggini, Massimo
Hirsch, Emilio
Falasca, Marco
Maffucci, Tania
Funding for this research was provided by:
Prostate Cancer UK (PG13-029)
Fondazione Italiana per la Ricerca sul Cancro (FIRC 19421)
Associazione Italiana per la Ricerca sul Cancro (AIRC 21875)
Article History
Received: 23 April 2019
Accepted: 4 November 2019
First Online: 21 November 2019
Ethics approval and consent to participate
: Procedures involving animals and their care were conducted in conformity with institutional guidelines that are in compliance with National Governing Law (D. lg 26/2014; Authorization no.19/2008-A issued March 6, 2008 by Ministry of Health, Italy) and International EU directive and guidelines (EEC Council Directive 2010/63/UE). The Statement of Compliance (Assurance) with the Public Health Service (PHS) Policy on Human Care and Use of Laboratory Animals was recently reviewed (9/9/2014) and will expire on September 30, 2019 (Animal Welfare Assurance #A5023–01).
: Not applicable.
: EH is a co-founder of Kither Biotech, a company involved in the development of PI3K inhibitors. The other authors declare that they have no competing interests.